20 April 2015

Bayer Indonesia Launches Latest Oral Contraception Containing Estradiol Valerate with Additional Benefits to Treat Heavy Menstrual Bleeding (HMB)

Oral contraception that delivers estradiol, a hormone that has similar biological effects as natural estrogen produced by a woman’s body

  • Clinically proven (99%) to be effective for preventing pregnancy with precise dosage
  • Clinically proven to treat Heavy Menstrual Bleeding (HMB) in women without organic pathology (abnormality of the reproductive organ)


Jakarta, 20 April 2015, Bayer Indonesia launches latest oral contraceptive whose estrogen component is based on estradiol, the same estrogen that is produced in the female body.

For the first time, this new oral contraceptive from Bayer uses a combination of estradiol valerate and dienogest in a unique dosage for a 28-day regiment, which consists of 26 pills containing hormones and 2 placebo pills.

The oral contraceptive with estradiol valerate and dienogest from Bayer was developed to help modern women to have the choice for the right contraception that can best suit their physical requirement. A dynamic, modern woman requires oral contraception that matches her body well so that she can maintain her vigor and remain active daily. A clinical study involving more than 2,200 women between the ages of 18 to 50 years old has proven that oral contraception with estradiol valerate and dienogest is effective as a combined oral contraceptive.

In addition to preventing pregnancy, this new oral contraceptive from Bayer containing estradiol valerate and dienogest hormones, is the first oral contraceptive to be clinically proven to have the additional benefit treatment of Heavy Menstrual Bleeding (HMB) for women without organic pathology (abnormality of the reproductive organ).

Approximately 52% of women have experienced HMB in their lifetime4. HMB is a common condition where women sustain menstrual bleeding of around ≥ 80 mL per cycle (1 spoon = 15ml) or using more than 1 (one) sanitary napkin every hour continously. However, HMB is often neglected even though it has a tremendous effect on the woman and her body.

A different clinical study has also shown that this latest oral contraceptive is an effective option for women to improve the HMB condition faster, more sustainable, and significantly after one month treatment5. This oral contraceptive from Bayer decreases menstrual bleeding by almost 88% after a six month treatment compared to the condition before the therapy6,7. It has also been significantly proven to improve the hemoglobin and ferritin (iron substance) levels of women suffering HMB.

“Today’s modern women have a deeper understanding on living a healthy life and really take into consideration about what they put into their body on a daily basis. They will look for contraception that they can rely on to help keep their body balanced,” said Prof. Calaf.

Furthermore, Prof. Calaf said that this new contraceptive from Bayer was uniquely designed to work hormonously with a woman’s body by providing proper levels of estrogen and progestin at the right moment during the cycle. Therefore, this oral contraceptive could be relied on by women in order to have a good menstrual cycle9,10 as well as to help maintain the estradiol to stay within the normal level during the first few days of the natural menstrual cycle.

Prof. Biran Affandi added, “Every woman needs a different type of contraception. It is also important to provide sufficient information regarding the types of oral contraception suitable to meet their lifestyle and needs. As women’s education and the social status progress, they will seek further information on oral contraceptive pill that best suit their lifestyles. Women who choose to use this oral contraceptive have shown a high level of satisfaction and 9 out of 10 say that they experience some improvements in their quality of life.

President Director of PT Bayer Indonesia Ashraf Al-Ouf said, “As the market leader in female contraception globally including Indonesia, Bayer remains committed to offer women and their healthcare providers a wide range of hormonal contraceptives to recognize women’s individual needs and their choices regarding contraception. This oral contraceptive has earned the international approval from the United States Food and Drug Administration (FDA) in 2009 and the legal permission from the Indonesian National Agency of Drugs and Foods Control (BPOM) in October 2013 for the treatment of heavy menstrual bleeding without organic pathology. The launch of this oral contraceptive today in Indonesia proves Bayer’s commitment in innovation as well as marks the beginning of a new era in oral contraception.”

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,888 people and had sales of €42.2 billion (IDR 588,000 Trillion). Capital expenditures amounted to €2.5 billion (IDR 35,000 Trillion), and R&D expenses to €3.6 billion (IDR 50,400 Trillion). For more information, go to www.bayer.com.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 20,0 billion (2014) or IDR 280,000 Trillion, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

Media Contact:
Anton Susanto
Head of Corporate Communication
PT Bayer Indonesia
Phone: +62-21-30491506
E-mail: anton.susanto@bayer.com


Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.